Teva’s $40 million payment “cannot be divorced from what Teva did not pay,” Judge Leonard P. Stark wrote. By dropping the patent case, “Amgen was permitting Teva to retain at least some of the” nearly $400 million it “earned at Amgen’s expense” during the one-week “at risk” launch of its Sensipar ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.